# LeMaitre Vascular, Inc. (LMAT)

> Source: Nexqual · https://nexqual.com/LMAT · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, LeMaitre Vascular, Inc. (LMAT), nexqual.com/LMAT" · informational, not investment advice.

**Price:** USD 83.16 (+0.65% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 82.62 · day 82.87–84.66 · 52w 78.22–118.01 · market cap $1.90B · NGM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $262M, net income $65.7M (25.0% margin), free cash flow $73.8M (SEC filings).
- Valuation: P/E 29.0x (avg 40.7x at the last 3 fiscal year-ends).
- Analysts: Buy (mean 2.25 on a 1–5 scale) (8 analysts), mean target USD 107 (range 81–132).
- Total return with dividends: 1Y -3.3% vs S&P 500 +18.1%; 5Y +62.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD 0.69, revenue estimate $67.4M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $154M | $162M | $193M | $220M | $250M | $262M |
| Gross profit | $101M | $105M | $127M | $151M | $179M | — |
| Operating income | $36.4M | $26.8M | $36.7M | $52.3M | $67.9M | $77.3M |
| Net income | $26.9M | $20.6M | $30.1M | $44.0M | $57.7M | $65.7M |
| EPS (diluted) | $1.25 | $0.93 | $1.34 | $1.93 | $2.52 | — |
| Free cash flow | $30.2M | $22.1M | $29.5M | $37.2M | $74.5M | $73.8M |
| Gross margin | 65.7% | 64.9% | 65.7% | 68.6% | 71.5% | — |
| Operating margin | 23.6% | 16.6% | 19.0% | 23.8% | 27.2% | 29.5% |
| Net margin | 17.4% | 12.8% | 15.6% | 20.0% | 23.1% | 25.0% |
| Revenue growth | +19.4% | +4.7% | +19.7% | +13.6% | +13.5% | — |
| Cash + short-term investments | $70.0M | $82.7M | $105M | $300M | $359M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 29.0x · P/S 7.3x · P/FCF 25.8x · P/B 4.5x · FCF yield 3.88% · Earnings yield 3.45% · Dividend yield (paid, TTM) 1.08% · Buyback yield (TTM) 0.09%
P/E at fiscal year-ends: Dec 2025 32.2x, Dec 2024 47.7x, Dec 2023 42.3x.

## Analysts
Consensus Buy (mean 2.25 on a 1–5 scale), 8 analysts; mean target USD 107 (low 81, high 132).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-05 | Wells Fargo | Target lowered | Equal-Weight | $104 → $94 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -3.3% | +62.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -3.3% | +10.2% |
| Volatility (annualized) | 45.8% | 35.5% |
| Max drawdown | -32.5% (Apr 2026→Aug 2026) | -31.3% (Jun 2023→Oct 2023) |

## Peers (Medical Instruments & Supplies)
XRAY (DENTSPLY SIRONA Inc.) USD 8.83 +3.76% · KMTS (Kestra Medical Technologies, Lt) USD 28.68 +6.34% · AZTA (Azenta, Inc.) USD 36.52 -3.56% · ATRC (AtriCure, Inc.) USD 57.78 +1.60% · WRBY (Warby Parker Inc.) USD 24.59 -7.28% · STAA (STAAR Surgical Company) USD 22.26 +3.53%

## More
Full page: https://nexqual.com/LMAT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt